Trader Fortress Biotech - FBIO CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | - | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.025457% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.003235% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Fortress Biotech Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Chiffres clés
| Fermeture précédente* | N/A |
| Ouvert* | N/A |
| Variation sur 1 an* | N/A |
| Fourchette du jour* | N/A |
| Fourchette sur 52 semaines | 0.48-1.33 |
| Volume moyen (10 jours) | 1.45M |
| Volume moyen (3 mois) | 15.00M |
| Capitalisation boursière | 73.74M |
| Ratio C/B | -100.00K |
| Actions en circulation | 134.33M |
| Revenu | 64.25M |
| EPS | -1.00 |
| Dividende (rendement en %) | N/A |
| Bêta | 2.00 |
| Prochaine date de publication des résultats | Aug 9, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|
Fortress Biotech Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| Wednesday, June 14, 2023 | ||
| Heure (UTC) (UTC) 12:00 | Pays US
| Événement Fortress Biotech Inc Fortress Biotech IncForecast -Previous - |
| Wednesday, June 21, 2023 | ||
| Heure (UTC) (UTC) 14:00 | Pays US
| Événement Fortress Biotech Inc Annual Shareholders Meeting Fortress Biotech Inc Annual Shareholders MeetingForecast -Previous - |
| Heure (UTC) (UTC) 14:00 | Pays US
| Événement Fortress Biotech Inc Annual Shareholders Meeting Fortress Biotech Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 9, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q2 2023 Fortress Biotech Inc Earnings Release Q2 2023 Fortress Biotech Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Heure (UTC) (UTC) 21:01 | Pays US
| Événement Q3 2023 Fortress Biotech Inc Earnings Release Q3 2023 Fortress Biotech Inc Earnings ReleaseForecast -Previous - |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu total | 75.743 | 68.791 | 45.599 | 36.629 | 26.882 |
| Revenu | 75.743 | 68.791 | 45.599 | 36.629 | 26.882 |
| Coût des recettes, total | 30.775 | 32.084 | 14.594 | 10.532 | 6.125 |
| Résultat brut | 44.968 | 36.707 | 31.005 | 26.097 | 20.757 |
| Total des frais d'exploitation | 279.307 | 257.332 | 139.869 | 128.972 | 146.442 |
| Total des frais de vente/Généraux/Admin | 113.656 | 86.843 | 61.166 | 55.59 | 53.371 |
| Recherche et développement | 134.876 | 128.865 | 64.109 | 81.326 | 87.383 |
| Charges (revenus) inhabituelles | 0 | 9.54 | 0 | -18.476 | -0.437 |
| Other Operating Expenses, Total | |||||
| Produits d'exploitation | -203.564 | -188.541 | -94.27 | -92.343 | -119.56 |
| Produits (charges) d'intérêts, nets Hors exploitation | -11.204 | 24.188 | -8.579 | -9.317 | -11.308 |
| Résultat net avant impôts | -213.464 | -164.353 | -102.849 | -101.66 | -130.8 |
| Résultat net après impôts | -213.913 | -164.826 | -102.985 | -101.66 | -130.8 |
| Intérêts minoritaires | 127.338 | 100.123 | 56.459 | 61.7 | 57.789 |
| Résultat net avant éléments extra | -86.575 | -64.703 | -46.526 | -39.96 | -73.011 |
| Résultat net | -86.575 | -64.703 | -46.526 | -39.96 | -84.147 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -86.575 | -64.703 | -46.526 | -39.96 | -73.011 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -86.575 | -64.703 | -46.526 | -39.96 | -84.147 |
| Résultat net dilué | -86.575 | -64.703 | -46.526 | -39.96 | -84.147 |
| Moyenne pondérée des actions diluées | 88.8745 | 81.7002 | 72.0052 | 54.7118 | 43.462 |
| BPA dilué hors éléments extraordinaires | -0.97413 | -0.79196 | -0.64615 | -0.73037 | -1.67988 |
| Dividends per Share - Common Stock Primary Issue | |||||
| BPA dilué normalisé | -0.97413 | -0.71606 | -0.64615 | -1.06807 | -1.68994 |
| Autres, nets | 1.304 | 0 | 0.068 | ||
| Total des éléments extraordinaires | 0 | -11.136 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Revenu total | 12.429 | 16.404 | 16.528 | 18.886 | 23.925 |
| Revenu | 12.429 | 16.404 | 16.528 | 18.886 | 23.925 |
| Coût des recettes, total | 6.449 | 7.718 | 7.221 | 7.633 | 8.203 |
| Résultat brut | 5.98 | 8.686 | 9.307 | 11.253 | 15.722 |
| Total des frais d'exploitation | 71.296 | 71.038 | 67.262 | 69.812 | 71.195 |
| Total des frais de vente/Généraux/Admin | 25.341 | 28.199 | 30.139 | 29.048 | 26.27 |
| Recherche et développement | 39.506 | 35.121 | 29.902 | 33.131 | 36.722 |
| Produits d'exploitation | -58.867 | -54.634 | -50.734 | -50.926 | -47.27 |
| Produits (charges) d'intérêts, nets Hors exploitation | 3.371 | -2.997 | -2.995 | -3.004 | -2.208 |
| Résultat net avant impôts | -55.145 | -56.996 | -53.06 | -53.93 | -49.478 |
| Résultat net après impôts | -55.145 | -57.445 | -53.06 | -53.93 | -49.478 |
| Intérêts minoritaires | 33.608 | 30.497 | 30.549 | 32.574 | 33.718 |
| Résultat net avant éléments extra | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Résultat net | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Résultat net dilué | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Moyenne pondérée des actions diluées | 101.886 | 90.6222 | 89.4249 | 88.7435 | 86.2551 |
| BPA dilué hors éléments extraordinaires | -0.21138 | -0.29737 | -0.25173 | -0.24065 | -0.18271 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | -0.21138 | -0.29737 | -0.25173 | -0.24065 | -0.18271 |
| Charges (revenus) inhabituelles | 0 | 0 | |||
| Autres, nets | 0.351 | 0.635 | 0.669 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 230.432 | 346.462 | 266.15 | 156.252 | 111.207 |
| Espèces et placements à court terme | 178.266 | 305.744 | 233.351 | 136.858 | 83.112 |
| Trésorerie et équivalents | 178.266 | 305.744 | 233.351 | 136.858 | 65.508 |
| Investissements à court terme | 0 | 17.604 | |||
| Total des créances, nettes | 28.346 | 23.79 | 24.672 | 14.404 | 7.593 |
| Accounts Receivable - Trade, Net | 28.208 | 23.112 | 23.928 | 13.539 | 5.498 |
| Total Inventory | 14.159 | 9.862 | 1.404 | 0.857 | 0.678 |
| Prepaid Expenses | 9.661 | 7.066 | 6.723 | 4.133 | 6.735 |
| Other Current Assets, Total | 0 | 13.089 | |||
| Total Assets | 294.301 | 396.503 | 333.413 | 226.422 | 140.993 |
| Property/Plant/Equipment, Total - Net | 33.011 | 34.071 | 32.41 | 33.913 | 12.019 |
| Property/Plant/Equipment, Total - Gross | 45.457 | 43.465 | 39.176 | 38.399 | 14.583 |
| Accumulated Depreciation, Total | -12.446 | -9.394 | -6.766 | -4.486 | -2.564 |
| Goodwill, Net | |||||
| Intangibles, Net | 27.197 | 12.552 | 14.629 | 7.377 | 1.417 |
| Long Term Investments | 0 | 17.566 | 11.148 | 0 | |
| Other Long Term Assets, Total | 3.661 | 3.418 | 2.658 | 17.732 | 16.35 |
| Total Current Liabilities | 127.715 | 101.042 | 51.76 | 45.616 | 55.614 |
| Payable/Accrued | 19.857 | 19.986 | 17.054 | 22.906 | 34.216 |
| Accrued Expenses | 22.792 | 25.349 | 18.636 | 15.463 | 1.329 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 7.235 | 4.51 | 4.522 | 7.22 | 19.078 |
| Other Current Liabilities, Total | 20.587 | 3.768 | 0.136 | 0.027 | 0.991 |
| Total Liabilities | 252.58 | 287.829 | 233.075 | 200.207 | 139.141 |
| Total Long Term Debt | 93.142 | 46.564 | 59.814 | 82.426 | 60.425 |
| Long Term Debt | 93.142 | 46.564 | 59.814 | 82.426 | 60.425 |
| Minority Interest | 8.304 | 117.203 | 96.661 | 46.317 | 17.891 |
| Other Liabilities, Total | 23.419 | 23.02 | 24.84 | 25.848 | 5.211 |
| Total Equity | 41.721 | 108.674 | 100.338 | 26.215 | 1.852 |
| Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | 0.003 | 0.001 | 0.001 |
| Common Stock | 0.11 | 0.101 | 0.095 | 0.574 | 0.717 |
| Additional Paid-In Capital | 675.841 | 656.033 | 583 | 461.874 | 397.408 |
| Retained Earnings (Accumulated Deficit) | -634.233 | -547.463 | -482.76 | -436.234 | -396.274 |
| Total Liabilities & Shareholders’ Equity | 294.301 | 396.503 | 333.413 | 226.422 | 140.993 |
| Total Common Shares Outstanding | 110.494 | 101.436 | 94.8775 | 74.0274 | 57.8455 |
| Total Preferred Shares Outstanding | 3.42714 | 3.42714 | 3.42714 | 1.34117 | |
| Accounts Payable | 57.244 | 47.429 | 11.412 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 202.381 | 230.432 | 257.994 | 298.991 | 341.186 |
| Espèces et placements à court terme | 152.483 | 178.266 | 208.351 | 248.771 | 287.511 |
| Trésorerie et équivalents | 152.483 | 178.266 | 208.351 | 248.771 | 287.511 |
| Total des créances, nettes | 28.252 | 28.346 | 28.686 | 29.047 | 31.814 |
| Accounts Receivable - Trade, Net | 27.616 | 28.208 | 28.533 | 28.671 | 31.183 |
| Total Inventory | 13.278 | 14.159 | 15.23 | 16.053 | 16.137 |
| Prepaid Expenses | 8.368 | 9.661 | 5.727 | 5.12 | 5.724 |
| Total Assets | 263.551 | 294.301 | 323.561 | 363.955 | 407.93 |
| Property/Plant/Equipment, Total - Net | 31.661 | 33.011 | 33.529 | 32.137 | 32.995 |
| Property/Plant/Equipment, Total - Gross | 44.951 | 45.457 | 45.152 | 43.026 | 43.128 |
| Accumulated Depreciation, Total | -13.29 | -12.446 | -11.623 | -10.889 | -10.133 |
| Intangibles, Net | 26.128 | 27.197 | 28.424 | 29.44 | 30.457 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 3.381 | 3.661 | 3.614 | 3.387 | 3.292 |
| Total Current Liabilities | 129.473 | 127.715 | 106.303 | 104.921 | 103.14 |
| Payable/Accrued | 20.959 | 19.857 | 18.35 | 20.655 | 22.269 |
| Accrued Expenses | 21.107 | 22.792 | 21.973 | 21.038 | 26.596 |
| Notes Payable/Short Term Debt | 2.318 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2.288 | 7.235 | 9.122 | 7.487 | 7.363 |
| Other Current Liabilities, Total | 16.933 | 20.587 | 1.093 | 1.802 | 2.38 |
| Total Liabilities | 225.755 | 252.58 | 261.89 | 286.732 | 310.071 |
| Total Long Term Debt | 91.446 | 93.142 | 92.539 | 89.419 | 88.772 |
| Long Term Debt | 91.446 | 93.142 | 92.539 | 89.419 | 88.772 |
| Minority Interest | -17.99 | 8.304 | 39.681 | 70.479 | 95.719 |
| Other Liabilities, Total | 22.826 | 23.419 | 23.367 | 21.913 | 22.44 |
| Total Equity | 37.796 | 41.721 | 61.671 | 77.223 | 97.859 |
| Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
| Common Stock | 0.13 | 0.11 | 0.108 | 0.108 | 0.106 |
| Additional Paid-In Capital | 693.433 | 675.841 | 668.65 | 661.691 | 660.973 |
| Retained Earnings (Accumulated Deficit) | -655.77 | -634.233 | -607.09 | -584.579 | -563.223 |
| Total Liabilities & Shareholders’ Equity | 263.551 | 294.301 | 323.561 | 363.955 | 407.93 |
| Total Common Shares Outstanding | 130.417 | 110.494 | 108.259 | 107.718 | 106.322 |
| Total Preferred Shares Outstanding | 3.42714 | 3.42714 | 3.42714 | 3.42714 | 3.42714 |
| Accounts Payable | 65.868 | 57.244 | 55.765 | 53.939 | 44.532 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | -213.913 | -164.826 | -102.985 | -101.66 | -141.936 |
| Liquidités provenant des activités d'exploitation | -179.401 | -116.54 | -83.682 | -94.961 | -98.848 |
| Liquidités provenant des activités d'exploitation | 3.109 | 2.628 | 2.28 | 1.922 | 1.393 |
| Amortization | 4.277 | 2.474 | 1.42 | 1.174 | 0.666 |
| Deferred Taxes | |||||
| Éléments non monétaires | 27.841 | 6.811 | 20.384 | 8.444 | 35.293 |
| Intérêts payés en espèces | 9.419 | 6.918 | 8.821 | 5.9 | 4.729 |
| Variation du fonds de roulement | -0.715 | 36.373 | -4.781 | -4.841 | 5.736 |
| Flux de trésorerie liés aux activités d'investissement | -22.928 | 40.514 | -7.164 | 20.097 | 18.824 |
| Dépenses d'investissement | -2.715 | -4.966 | -3.126 | -4.745 | -8.282 |
| Autres éléments de flux de trésorerie d'investissement, total | -20.213 | 45.48 | -4.038 | 24.842 | 27.106 |
| Flux de trésorerie provenant des activités de financement | 75.319 | 148.994 | 172.41 | 146.714 | 50.648 |
| Éléments de flux de trésorerie de financement | 14.156 | 119.232 | 41.47 | 76.118 | 20.309 |
| Total Cash Dividends Paid | -8.78 | -8.78 | -6.752 | -2.559 | -2.344 |
| Émission (remboursement) d'actions, nette | 25.695 | 44.73 | 167.363 | 58.155 | 15.788 |
| Émission (remboursement) de la dette, nette | 44.248 | -6.188 | -29.671 | 15 | 16.895 |
| Variation nette de la trésorerie | -127.01 | 72.968 | 81.564 | 71.85 | -29.376 |
| Cash Taxes Paid | 0.858 | 0.993 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -55.145 | -213.913 | -156.468 | -103.408 | -49.478 |
| Cash From Operating Activities | -43.22 | -179.401 | -131.557 | -88.284 | -46.86 |
| Cash From Operating Activities | 0.844 | 3.109 | 2.286 | 1.495 | 0.739 |
| Amortization | 1.069 | 4.277 | 3.05 | 2.034 | 1.017 |
| Non-Cash Items | 3.866 | 27.841 | 21.303 | 13.056 | 6.519 |
| Cash Interest Paid | 2.885 | 9.419 | 6.595 | 3.987 | 1.556 |
| Changes in Working Capital | 6.146 | -0.715 | -1.728 | -1.461 | -5.657 |
| Cash From Investing Activities | -5 | -22.928 | -22.537 | -21.644 | -21.337 |
| Capital Expenditures | 0 | -2.715 | -2.624 | -1.644 | -1.337 |
| Cash From Financing Activities | 22.187 | 75.319 | 56.701 | 52.955 | 49.964 |
| Financing Cash Flow Items | 9.703 | 14.156 | 13.997 | 12.309 | 5.745 |
| Total Cash Dividends Paid | -2.194 | -8.78 | -6.587 | -4.391 | -2.195 |
| Issuance (Retirement) of Stock, Net | 14.626 | 25.695 | 5.991 | 5.737 | 4.226 |
| Issuance (Retirement) of Debt, Net | 0.052 | 44.248 | 43.3 | 39.3 | 42.188 |
| Net Change in Cash | -26.033 | -127.01 | -97.393 | -56.973 | -18.233 |
| Other Investing Cash Flow Items, Total | -5 | -20.213 | -19.913 | -20 | -20 |
| Cash Taxes Paid | 0.858 | 1.462 | 0.166 | 0.107 |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| Rosenwald (Lindsay A M.D.) | Individual Investor | 11.4268 | 15349091 | 0 | 2023-03-31 | LOW |
| Weiss (Michael S) | Individual Investor | 10.9823 | 14752034 | 0 | 2023-03-31 | LOW |
| Nantahala Capital Management, LLC | Hedge Fund | 5.1501 | 6917876 | -1050180 | 2023-03-31 | LOW |
| Dak Capital Inc | Corporation | 4.5062 | 6052975 | 6052975 | 2023-02-10 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8973 | 5235107 | 130700 | 2023-03-31 | LOW |
| Opaleye Management Inc. | Hedge Fund | 3.4049 | 4573600 | 2523600 | 2023-03-31 | LOW |
| Jefferies LLC | Research Firm | 2.1217 | 2850000 | -1450000 | 2023-03-31 | HIGH |
| Lobell (J Jay) | Individual Investor | 1.2175 | 1635401 | 0 | 2023-03-31 | LOW |
| Jin (David) | Individual Investor | 1.113 | 1495007 | 1350000 | 2023-03-31 | HIGH |
| Perkins Capital Management, Inc. | Investment Advisor | 1.0564 | 1419013 | 596500 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.0346 | 1389678 | -3845 | 2023-03-31 | LOW |
| Medical Strategy GmbH | Investment Advisor | 1.0268 | 1379308 | -156278 | 2023-01-31 | LOW |
| Shikiar Asset Management, Inc. | Investment Advisor | 0.8703 | 1169000 | 327500 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.761 | 1022233 | 263672 | 2023-03-31 | MED |
| Rowinsky (Eric K. M.D.) | Individual Investor | 0.7113 | 955466 | 223490 | 2023-03-31 | |
| CI Private Wealth, LLC | Investment Advisor | 0.6812 | 915053 | 122786 | 2023-03-31 | |
| Foord Asset Management (Pty) Limited | Investment Advisor/Hedge Fund | 0.5874 | 789080 | 586820 | 2022-06-30 | LOW |
| Columbia Pacific Wealth Management | Investment Advisor | 0.5675 | 762267 | -19500 | 2022-09-30 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5198 | 698287 | 20065 | 2023-03-31 | LOW |
| Avgerinos (George C) | Individual Investor | 0.4877 | 655170 | 0 | 2023-03-31 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group530K+
Tradeurs
87K+
Clients actifs par mois
$46M+
Volume d'investissement par mois
$31M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Fortress Biotech Company profile
À propos de Fortress Biotech
Fortress Biotech, Inc. (Fortress) est une société biopharmaceutique qui acquiert, développe et commercialise des produits pharmaceutiques et biotechnologiques et des produits candidats. Fortress a sept produits pharmaceutiques sur ordonnance commercialisés et plus de 25 programmes en cours de développement chez Fortress et dans ses entreprises partenaires. Ses produits candidats couvrent six secteurs de marché, dont l'oncologie, les maladies rares et la thérapie génique. Les produits commercialisés de la société comprennent Ximino, Targadox, Exelderm, Ceracade, Luxamend et Accutane. Ses produits candidats en phase avancée de développement comprennent le Tramadol intraveineux (IV), CUTX-101, MB-107 et MB-207, Cosibelimab, CK-101, CAEL-101, Triplex et CEVA101. Ses produits candidats comprennent également MB-102 (CD123 CAR T pour le BPDCN), MB-101 (IL13Ra2 CAR T pour le glioblastome), MB-104, MB-106, MB-103, AVTS-001, CK-103 et ConVax. La société opère dans deux secteurs d'activité et de rapport : Ventes de produits dermatologiques, et Développement de produits pharmaceutiques et biotechnologiques.
| Industry: | Biopharmaceuticals |
1111 Kane Concourse
Suite 301
BAY HARBOR ISLANDS
FLORIDA 33154
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 530 000 traders du monde entier qui ont choisi de trader avec Capital.com